MAYWOOD, N.J., Jan. 17, 2001 (PRIMEZONE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that its shares have been recommended in an analyst report just released by WallStreet Research, a prominent research boutique led by Alan Stone, Managing Director of Alan Stone & Company, LLC. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management and an investment analyst at Prudential Insurance Company's Capital Markets Group.
WallStreet Research specializes in the microcap and smallcap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. The report on Nymox Pharmaceutical Corporation is available, together with additional information about WallStreet Research, at www.WallStreetResearch.org.
Nymox Pharmaceutical Corporation, founded in 1989 and based in Maywood, NJ and Montreal, Canada, is a diversified biopharmaceutical research and development company with two unique proprietary products on the market, and a significant R&D pipeline of products in development. The Company specializes in products for diagnosis and treatment of Alzheimer's disease (AD), an affliction of more than 15 million aging people around the world. Through its clinical reference laboratory in Maywood, New Jersey, the Company markets a proprietary diagnostic test called AlzheimAlert(tm), the only commercially available urine test for AD and has two separate programs to develop treatment for the disease. The Company's second proprietary product, developed by the Company's 98% owned subsidiary Serex, Inc. and marketed as NicAlert(tm), is an inexpensive, simple-to-use urine or saliva test strip that determines whether a person is using tobacco products. The Company also has several antibacterials in development. Trading on Nasdaq Small Cap Marketplace under the symbol NYMX, the Company is capitalizing on its over-decade-long research, emerging as a leader in Alzheimer's disease diagnostics and therapeutics.
Additional information on Nymox Pharmaceutical Corporation's programs and developments is available on the company's Web site at www.nymox.com or in the WallStreet Research report at www.WallStreetResearch.org.
This press release contains certain ``forward-looking statements'' as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.